A pilot, open labelled, randomised controlled trial of hypertonic saline nasal irrigation and gargling for the common cold

Abstract

There are no antivirals to treat viral upper respiratory tract infection (URTI). Since numerous viruses cause URTI, antiviral therapy is impractical. As we have evidence of chloride-ion dependent innate antiviral response in epithelial cells, we conducted a pilot, non-blinded, randomised controlled trial of hypertonic saline nasal irrigation and gargling (HSNIG) vs standard care on healthy adults within 48 hours of URTI onset to assess recruitment (primary outcome). Acceptability, symptom duration and viral shedding were secondary outcomes. Participants maintained a symptom diary until well for two days or a maximum of 14 days and collected 5 sequential mid-turbinate swabs to measure viral shedding. The intervention arm prepared hypertonic saline and performed HSNIG. We recruited 68 participants (2.6 participants/week; November 2014-March 2015). A participant declined after randomisation. Another was on antibiotics and hence removed (Intervention:32, Control:34). Follow up data was available from 61 (Intervention:30, Control:31). 87% found HSNIG acceptable, 93% thought HSNIG made a difference to their symptoms. In the intervention arm, duration of illness was lower by 1.9 days (p = 0.01), over-the-counter medications (OTCM) use by 36% (p = 0.004), transmission within household contacts by 35% (p = 0.006) and viral shedding by ≥0.5 log10/day (p = 0.04). We hence need a larger trial to confirm our findings.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1

Expected and actual recruitment: Recruitment of participants from the 1st October 2014 till close of recruitment on 31st March 2015. If we take the full 26-week period, this would result in an average of 2.6 participants per week over the study period. However, if we were to take the first and last recruitment dates this give a period of 20 weeks which results in an average of 3.4 participants per week.

Figure 2

Consort Flow diagram: Based on the “CONSORT extension for Pilot and Feasibility Trials Flow Diagram” (http://www.consort-statement.org/downloads/extensions - Accessed 04/12/2018).

Figure 3

Response from participants over the study period: Each line represents response of a participant over 14 days. Data is shown by treatment group. The global severity question was “How unwell do you feel today”. The responses were graded from 0 (Not unwell), 1 (very mildly), 3 (mildly), 5 (moderately) and 7 (severely unwell). Likewise, each symptom was graded 0 (no symptom) to 7 (severe).

Figure 4

Severity of symptoms, viral shedding and relationship to HSNIG and participant number in each arm: For each participant, the daily scores for the global question ‘how unwell do you feel today’ over 14 days are represented by the grey background. For the intervention arm (shown on the left), the blue columns represent the number of times HSNIG was done that day. For both arms, change in viral shedding (as log values; Red line) is shown for the corresponding days.